Justin Stebbing
Oncology Professor in United Kingdom
Justin trained at Trinity College, Oxford where he earned a first-class degree. After junior doctor posts there, he undertook a medicine residency at Johns Hopkins Hospital, USA, then continuing at The Royal Marsden, St Bart's Hospitals. He was from 2009-2022 Professor of Oncology at Imperial College.
He has published over 650 peer-reviewed papers in journals including The Lancet, New England Journal, Blood, the Journal of Clinical Oncology, Annals of Internal Medicine. His focus has been on immunotherapies and genomics. The charity Action Against Cancer supports him.
He is a Fellow of the Royal College of Physicians, the Royal College of Pathologists and sits on many biopharmaceutical advisory boards. Justin's team published in Nature Medicine the discovery of a new cancer-causing gene. Recent papers include use of biosimilars, increasing access across the developing world.
He was appointed the first NIHR oncology professor in 2011. In 2016, he was recognised as co-Editor-in-Chief of Oncogene and to the American Society for Clinical Investigation.
At the pandemic's start, Justin published pieces in the Lancet using artificial intelligence to find a new drug. His work on mechanistic studies and trials helped gain FDA approval for hospitalised patients with the highest mortality benefit. Justin's book ‘Witness to Covid’ describes this, with a foreword by Sid Mukherjee, a joint lecture here. In 2022 he resigned from Imperial. He was made Visiting Professor and has an active research program there.